Cytokine Signalling Forum

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr. David Martin, executive medical director at Pfizer in Massachusetts, USA as they discuss his recent paper 'Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors' Detailed summary slides of this paper and many more publications, are free to view and download in the publications section at cytokinesignalling.com.

Join Professor Iain McInnes in this month's CSF Podcast, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that look at the epidemiology of autoimmune diseases. The first paper, the GBD 2021 Rheumatoid Arthritis Collaborators systematically reviewed the global RA burden, and used these data to predict prevalence up to 2050 and the second paper, Nathalie Conrad and her colleagues reported the incidence and prevalence of 19 different autoimmune disorders in the United Kingdom, while also stratifying by age, sex, and socioeconomic status. To access detailed summary slides for the papers discussed today, visit cytokinesignalling.com.

Join Professor Peter Nash from the Griffith University in Brisbane and Dr. Andreas Kerschbaumer of the Division of Rheumatology, Department of Internal Medicine, Medical University of Vienna, Austria, as they discuss an important presentation from this year’s EULAR congress. ‘EULAR Recommendations for the Management of Psoriatic Arthritis: 2023 Update’.

Professor Peter Nash from the Griffith University in Brisbane, is joined by Professor Martin Bergman, a Clinical Associate Professor of Medicine at the Drexel University College of Medicine in Philadelphia, to discuss his recent paper ‘One-Year Medication Adherence and Persistence in Rheumatoid Arthritis in Clinical Practice: A Retrospective Analysis of Upadacitinib, Adalimumab, Baricitinib, and Tofacitinib.’ Detailed summary slides of this paper and many more publications, are free to view and download in the publications section at cytokinesignalling.com.

Peter Nash, Professor at the School of Medicine, Griffith University, and Director of the Rheumatology Research Unit on the Sunshine Coast, Australia, is joined by Laura Coates, an Associate Professor, NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre as well as Doctor Frank Behrens, Medical director at Goethe-University. The papers covered in this topical discussion highlight two interesting areas of the modern PsA therapeutic landscape. The first of the publications discusses the safety and efficacy of upadacitinib in the treatment of patients with PsA and an inadequate response to bDMARDs through a three-year study. The second, explores an analysis of the real-world safety profile of tofacitinib in the treatment of patients with PsA. If you would like to read more about the topics discussed, head over to cytokinesignalling.com, where you’ll find detailed summary slides of each of the papers.

Dr Sofia Ramiro, consultant rheumatologist and senior researcher at Zuyderland Medical Centre and Leiden University Medical Centre in the Netherlands, is joined by Professor Hideto Kameda, Professor of Internal Medicine at Toho University and Atul Deodhar, Professor of Medicine and Medical Director of Rheumatology Clinics in the Division of Arthritis & Rheumatic Diseases at Oregon Health & Science University in Portland, USA to discuss the Efficacy and Safety of Ixekizumab & Tildrakizumab. In the first paper discussed, it describes the safety and efficacy of ixekizumab treatment in patients with r-axSpA and nr-axSpA for up to 156 weeks. The second study discussed goes on to assess the safety and efficacy of tildrakizumab in patients with active AS.

Join Prof Iain McInnes as he reviews two interesting papers , that retrospectively investigate the properties of JAK inhibitors. In our first paper, Peter Taylor and his colleagues review the pharmacological differences between JAK inhibitors, and how these may affect safety and efficacy. In the second, Qige Wei and colleagues carried out a network meta-analysis of 14 RCTS to identify any associations between RA therapies and MACE or all-cause mortality. To access detailed summary slides of the papers discussed, visit cytokinesignalling.com.

Professor Peter Nash from the Griffith University in Brisbane, is joined by Doctor Sofia Ramiro, a Consultant Rheumatologist and Senior Researcher at Leiden University Medical Centre to discuss her recent paper 'Do Fatty Lesions Explain the Effect of Inflammation on New Syndesmophytes in Patients with Radiographic Axial Spondyloarthritis? Results From the SIAS Cohort and ASSERT Trial'

Join Prof Iain McInnes as he reviews two interesting papers. Our first paper today by Charles-Schoeman and colleagues compared paraoxonase activity in RA patients treated with tofacitinib, with a focus of PON1 genotypes. Furthermore, the relationship between PON1 genotypes and the risk of MACE and malignancy were also investigated. In our second paper, Peter Taylor and colleagues evaluated the results of several baricitinib RCTs and real-world evidence studies.

Join Professor Hideto Kameda, and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. Our first paper aimed to use mediation modelling to determine whether tofacitinib improved fatigue symptoms directly or indirectly. Our second paper shows that IV-golimumab reduces fatigue symptoms in patients with ankylosing spondylitis.

Join Prof Iain McInnes as he reviews two interesting papers. Our first paper today by Roy Fleischmann and his colleagues compares the incidence of serious adverse events in RA patients with a higher risk of cardiovascular events and the overall RA population in a post-hoc study. They also compared the incidence rate of adverse events for upadacitinib, adalimumab and methotrexate, or methotrexate monotherapy. In our second paper, Mohammed Khan and colleagues compared tofacitinib against methotrexate as first-line therapies against RA, with a focus on treatment remission.

Join Peter Nash, Professor at the School of Medicine, Griffith University, and Director of the Rheumatology Research Unit on the Sunshine Coast, Australia, Laura Coates, an Associate Professor, NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre and Doctor Frank Behrens, Medical director at Goethe-University, as they discuss two interesting areas of the modern PsA therapeutic landscape. The first of the publications discussed pertains to the use of secukinumab in oligoarticular PsA. We will then go on to expand upon the latest in the evolving story begun by ORAL Surveillance, as we discuss the latest meta-analysis of the relationship between JAK inhibition and malignancies.

Professor Peter Nash from the Griffith University in Brisbane, is joined by Professor Laura Coates a NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre, discussing her recent paper 'Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study'.

Professor Peter Nash from the Griffith University in Brisbane, is joined by Dr Mark Russell, a clinical research fellow at the Centre for Rheumatic Diseases, King’s College London to discuss his recent paper 'JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications'.

Join Prof Iain McInnes as he reviews two interesting papers surrounding filgotinib and baricitinib. Our first paper today by Walter Reinisch and his colleagues highlight the latest update from the Phase 2 MANTA and MANTA-Ray studies, exploring the impact of filgotinib semen parameters and sex hormones in men with inflammatory diseases. In the second paper, David Simon and his team investigate the impact of baricitinib on volumetric bone mineral density and several other markers of bone health in RA patients.

Join Professors Atul Deodhar, Xenofon Baraliakos, Hideto Kameda, and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. Our first paper aimed to determine when the optimal time to start secukinumab treatment is demonstrated by a significant difference between baseline and post treatment BASDAI scores. Our second paper the goes on to evaluate a case report of a 45-year-old male, with AS, and adalimumab-induced refractory paradoxical palmoplantar pustulosis, after failure of prior secukinumab treatment.

Join Professor Peter Nash as he goes through our top abstracts, posters, and presentations from Day 4 of EULAR 2023 today (Saturday 3 June). They're all available right here on the CSF YouTube channel, so make sure you don't miss them!

Join Professor Lorenzo Dagna as she goes through our top abstracts, posters, and presentations from Day 3 of EULAR 2023 today (Friday 2 June). They're all available right here on the CSF YouTube channel, so make sure you don't miss them!

Join Dr Sofia Ramiro as she goes through our top abstracts, posters, and presentations from Day 2 of EULAR 2023 today (Thursday 1st June). They're all available right here on the CSF YouTube channel, so make sure you don't miss them!

Join Prof Iain McInnes in today’s podcast, where he will be reviewing two papers that investigate treatments for RA patients. In the first paper, Philip Conaghan and colleagues evaluate the effectiveness in a Bruton’s tyrosine kinase inhibitor in treating rheumatoid arthritis in patients with an inadequate response to methotrexate. In the second paper, Vincenzo Venerito and his team assessed the recombinant zoster vaccine in rheumatoid arthritis patients that are treated with JAK inhibitors.